

BIOFLAVONOIDS CLASSIFICATION, PHARMACOLOGICAL, BIOCHEMICAL EFFECTS AND THERAPEUTIC POTENTIAL

K. RAJ NARAYANA, M. SRIPAL REDDY, M.R. CHALUVADI,
D.R. KRISHNA*

Drug Metabolism & Clin. Pharmacokinetics Division, University College of Pharmaceutical Sciences, Kakatiya University, Warangal-506 009.

Manuscript Received:15.3.2000

Revised: 9.5.2000

Accepted: 10.6.2000

SUMMARY Flavonoids belong to a group of polyphenolic compounds, which are classified as flavonols, flavonones, flavones, flavanols, flavan-3-ols and isoflavones according to the positions of the substitutes present on the parent molecule. Flavonoids of different classes have several pharmacological activities. Flavonoids have also been known to possess biochemical effects, which inhibit a number of enzymes such as aldose reductase, xanthine oxidase, phosphodiesterase, Ca²⁺-ATPase, lipoxygenase, cyclooxygenase, etc. They also have a regulatory role on different hormones like estrogens, androgens and thyroid hormone. In view of their wide pharmacological and biological actions, they seem to be having a great therapeutic potential.

KEYWORDS Flavonoids biochemistry pharmacology therapeutic potential

INTRODUCTION

Flavonoids are a group of polyphenolic compounds, which are widely distributed through out the plant kingdom. To date about 3000 varieties of flavonoids are known¹. Many have low toxicity in mammals and some of them are widely used in medicine for maintenance of capillary integrity². Flavonoids exhibit several biological effects such as antiinflammatory, anti hepatotoxic and anti-ulcer actions^{3,4}. They also inhibit enzymes such as aldose reductase and xanthine oxidase. They are potent antioxidants and have free radical scavenging abilities. Many have antiallergic, antiviral actions and some of them provide protection against cardiovascular mortality^{5,6}. They have been shown to inhibit the growth of various cancer cell lines *in vitro*, and reduce tumour development in experimental animals⁷. In this review we have attempted to describe the present status of their classification, pharmacological/biochemical effects and their therapeutic potential.

Structure and classification of flavonoids:

Flavonoids occur as aglycones, glycosides and methylated derivatives. The flavonoid aglycone consists

of a benzene ring (A) condensed with a six-membered ring (C), which in the 2-position carries a phenyl ring (B) as a substituent (Figure 1). Six-member ring condensed with the benzene ring is either a α -pyrone (flavonols and flavonones) or its dihydroderivative (flavanols and flavanones). The position of the benzenoid substituent divides the flavonoid class into flavonoids (2-position) and isoflavonoids (3-position). Flavonols differ from flavonones by hydroxyl group the 3-position and a C₂-C₃ double bonds⁸. Flavonoids are often hydroxylated in position 3,5,7,2',3',4',5'. Methyl ethers and acetyl esters of the alcohol group are known to occur in nature. When glycosides are formed, the glycosidic linkage is normally located in positions 3 or 7 and the carbohydrate can be L-rhamnose, D-glucose, galactose or arabinose⁹. The most common flavonoids are listed in Table 1.

I. Pharmacological Effects of Flavonoids

1. CNS Activity:

Synthetic flavonoids like 6-bromoflavone and 6-bromo-3'-nitro- flavones were shown to displace [3H] flumazenil binding to membranes from rat

*Correspondence: D.R. Krishna
e-mail: dr_krishna@rediffmail.com

Table 1. Nomenclature of the subclasses of flavonoids based on the position of their substituents.

| | 3 | 5 | 7 | 2' | 3' | 4' | 5' |
|---------------|------------------|------|------------------|----|----|---------|----|
| Flavonols: | | | | | | | |
| Kaempferol | OH | OH | OH | H | H | OH | H |
| Morin | OH | OH | OH | OH | H | OH | H |
| Rutin | O-R ¹ | OH | OH | H | OH | OH | H |
| Myricetin | OH | OH | OH | H | OH | OH | OH |
| Quercetin | OH | OH | OH | H | OH | OH | H |
| Quercetrin | O-Rh | OH | OH | H | OH | OH | H |
| Myricitrin | O-Rh | OH | OH | H | OH | OH | OH |
| Spirenoside | OH | OH | OH | H | OH | O-Glu | H |
| Galangin | OH | OH | OH | H | H | H | H |
| Robinin | O-R ¹ | OH | OH | H | H | OH | H |
| Kaempferide | OH | OH | OH | H | H | O-Me | H |
| Fisetin | OH | H | OH | H | OH | OH | H |
| Rhamnetin | OH | OH | O-Me | H | OH | OH | H |
| Flavonones: | | | | | | | |
| Hesperitin | H | OH | OH | H | OH | O-Me | H |
| Naringin | H | OH | O-R | H | H | OH | H |
| Naringenin | H | OH | OH | H | H | OH | H |
| Eriodictyol | H | OH | OH | H | OH | OH | H |
| Hesperidin | H | OH | O-Me | H | OH | O-Me | H |
| Pinocembrin | H | OH | OH | H | H | H | H |
| Likvirutin | H | H | OH | H | H | O-Glu H | H |
| Flavones: | | | | | | | |
| Rpofolin | H | OH | O-R | H | H | OH | H |
| Apigenin | H | OH | OH | H | H | OH | H |
| Tangeretin | H | O-Me | O-Me | H | H | O-Me | H |
| Flavone | H | H | H | H | H | H | H |
| Baicalein | H | OH | OH | H | H | H | H |
| Luteolin | H | OH | OH | H | OH | OH | H |
| Chrysin | H | OH | OH | H | H | H | H |
| Techtochrysin | H | OH | O-Me | H | H | H | H |
| Diosmetin | H | OH | OH | H | OH | O-Me | H |
| Diosmin | H | OH | O-R ¹ | H | OH | O-Me | H |
| Flavanolols: | | | | | | | |
| Silibinin | OH | OH | OH | H | H | O-L-O- | H |
| Silymarin | OH | OH | OH | H | H | O-L-O- | H |
| Taxifolin | OH | OH | OH | H | OH | OH | H |
| Pinobanksin | OH | OH | OH | H | H | H | H |
| Flavan-3-ols: | | | | | | | |
| Catechin | OH | OH | OH | H | OH | OH | H |
| Isoflavones: | | | | | | | |
| Genistein | - | OH | OH | H | H | OH | H |
| Daidzin | - | H | O-Glu | H | H | OH | H |


-O-Me = Methoxy

-O-Glu = Glucosyl


-O-R¹ = Alkoxy

-O-L-O = Selaone


Figure 1. Basic structure of various flavonoids and related compounds.




Flavan-3-ols




Flavonols




Benzo- γ -pyrone




Coumarin




Chalcone




Flavonol




Isoflavonol




Flavone




Isoflavone




Flavonone



Isoflavonone



Flavonol



Isoflavonol

cerebellum but not from spinal cord, indicating selectivity for the BZ-Omega receptor subtype, but latter was very potent than 6-bromoflavone. Results from two conflict tests in rats showed that these synthetic flavonoids possess anxiolytic like properties similar or superior to that of diazepam¹⁰.

2. Cardiotoxic activity:

Flavonoids have been reported to have action on the heart. The unsubstituted parent flavone exerts coronary dilatory activity and was commercially available under the name 'Chromocor' and its combination with routine and isoquercetin was also available with brand name 'flavoce', useful in the treatment of atherosclerosis. 3-methyl quercetin has positive chronotropic effect on guinea pig right atrium and antiarrhythmic effect on left atrium¹¹. In recent report the cardiotoxicity (negative inotropic effect) of doxorubicin on the mouse left atrium has been inhibited by flavonoids, 7-mono-hydroxy ethyl rutoside and 7,3',4'-trihydroxy-ethyl rutoside. In a recent review Huesken *et al.* gave detailed discussion on the cardioprotective effects of flavonoids¹².

The glycosides of luteolin, apigenin and genistein produced antihypertensive activity even more than the reference drug papaverine. Three flavonoids showed vasorelaxant effect in order of potency, luteolin > eriodictyol > naringenin on rat thoracic aorta.

Luteolin, apigenin and genistein exhibited their action through different mechanisms by inhibition of the calcium release from sarcoplasmic reticulum, enzymatic systems such as protein kinase-C and the calcium influx¹³. Different flavonoids were tested for a positive inotropic effect on guinea pig papillary muscle placed at 0.2 Hz in a Krebs-Henseleit solution at 30° C. Quercetin showed the most potent intrinsic activity, and produced the strongest inotropic responses among the different flavonoids. The relative order of potency of the tested flavonoids was, quercetin > morin = kaempferol > luteolin = apigenin > fisetin = galangin¹⁴.

3. Lipid lowering activity:

Oxidative modification of low-density lipoproteins (LDL) by free radicals is an early event in the pathogenesis of atherosclerosis. The rapid uptake of oxidatively modified LDL *via* a scavenger receptor leads

to the formation of foam cells. Oxidized LDL also has a number of other atherogenic properties. A number of mechanisms are likely to contribute to inhibition of LDL oxidation by flavonoids. Flavonoids may directly scavenge some radical species by acting as chain-breaking antioxidants¹⁵. In addition, they may recycle other chain-breaking antioxidants such as α -tocopherol by donating a hydrogen atom to the tocopheryl radical¹⁶. Transition metals such as iron and copper are important pro-oxidants, and some flavonoids can chelate divalent metal ions, hence preventing free radical formation. The ability of quercetin, and the quercetin glycosides, to protect LDL against oxidative modification has shown a significant protective effect¹⁷⁻¹⁹. Liquiritigenin showed a significant fall in serum cholesterol, LDL-cholesterol and atherogenic index. Influence of flavonoids on blood coagulation has been studied. The anticoagulant action of heparin was antagonized by flavonoids extracted from *T. hircanicum*. Ability of different flavonoids to inhibit the procoagulant activity of adherent human monocytes has been studied recently and hinokiflavone, a bioflavonoid has been found to be very most active in inhibiting the interleukin-1 β induced expression of tissue factor on human monocytes²⁰. Silymarin counteracts ethanol-induced lipid peroxidation injury by reducing liver MDA and raising GSH levels²².

4. GIT:

a) Antiulcer Activity:

Some recent reports have indicated that many flavonoids possess antiulcerogenic activity. Oral treatment with the ether fraction of the flavonoid extract demonstrated a good level of gastric protection. Mucous content was increased and accompanied by proportionate increase in proteins and hexosamines²¹. β Hydroxy ethyl rutosides, gossypin, naringin, naringenin and (+)-Cyanidanol-3 were shown to exhibit anti-ulcer activity²². Quercetin, rutin and kaempferol administered intraperitoneally (25-100 mg/kg) inhibited dose-dependent gastric damage produced by acidified ethanol in rats. Flavone was inactive while naringin was active at a higher dose (200 mg/kg). Quercetin, kaempferol, morin, myricetin and rutin when tested were found to inhibit the mucosal content of platelet activating factor (P AF) in a dose dependent manner suggesting that the protective role of these substances may be

mediated by endogenous PAF²². Quercetin, kaempferol, rutin produced an inhibitory effect on intestinal functions, and that their actions are mediated through α_2 -adrenergic and calcium systems²³. This result may show the beneficial effects in diarrhea and other intestinal secretions. Lorenz *et al*²⁵. Showed that (+)-Cyanidanol-3 has histidine decarboxylase inhibitory activity and hence anti-ulcer activity²⁵. 3-Methoxy-5,7,3',4'-tetra hydroxy flavan (Meciadanol), a congener of (+)-cyanidanol-3 exhibited significant anti-ulcer activity in pylorus ligated rats, restraint ulcers and gastric mucosal damage induced by aspirin models²².

b) Hepatoprotective activity:

Many flavonoids have also been found to possess hepato-protective activity. In a study carried out to investigate silymarin, apigenin, quercetin and naringenin as putative therapeutic agents against microcrystin LR- induced hepatotoxicity, silymarin was found to be the most effective one²⁴. Rutin and venorutin showed regenerative and hepato-protective effects in experimental cirrhosis²⁵. The results of several clinical investigations showed the efficacy and safety of flavonoids in the treatment of hepato-biliary dysfunction and digestive complaints, such as sensation of fullness, loss of appetite, nausea and abdominal pain. Silymarin normalizes cell phospholipid synthesis without showing any demonstrable effect on undamaged cells where by counteracting fatty liver. Moreover, earlier findings on a hepato-protective effect and the prevention of NSAIDs-induced gastropathy may be confirmed^{26,27}.

5. Antioxidant activity:

Free radical production in animal cells can either be accidental or deliberate. With the increasing acceptance of free radicals as common place and important biochemical intermediates, they have been implicated in a large number of human diseases^{28,29}.

Quercetin, kaempferol, morin, myricetin and rutin by acting as antioxidants exhibited several beneficial effects, such as antiinflammatory, antiallergic, antiviral as well as an anticancer activity. They have also been suggested to play a protective role in liver diseases, cataracts, and cardiovascular diseases. Quercetin and silybin acting as free radical scavengers were shown to exert a protective effect in reperfusion ischemic tissue damage³⁰⁻³². The scavenging activity of flavonoids has been reported to be in the or-

der: myricetin > quercetin > rhamnetin > morin > diosmetin > naringenin > apigenin > catechin > 5,7-dihydroxy-3',4',5'-trimethoxyflavone > robinin > kaempferol > flavone³³. Stabilization of meat lipids with flavonoids has been studied and morin, myricetin, kaempferol and quercetin at a level of 200 ppm were found to be most effective³⁴. Induction period of lipid oxidation in canola oil was delayed with the flavonoid myricetin by upto fifteen days. Formation of oxidation products was also inhibited by 69%, during this period. Morin, myricetin, kaempferol and quercetin have also been suggested as stabilizers for fish oil as an alternative to synthetic antioxidants³⁵.

6. Effect on heat shock proteins:

Heat shock proteins (HSP) have been recognized against physiological stress such as heat shock, heavy metals and glucose starvation. Recent progress has revealed the role of HSPs in various diseases. HSP27 has been shown to be involved in the acquired resistance of tumour cells, hyperthermic and chemotherapeutic treatment. Aberrant expression of HSP could cause various autoimmune diseases. Flavonoids inhibited the expression of HSP27, HSP47, and HSP72/73³⁶. The results suggested the pharmacological possibilities of flavonoids in diseases derived from abnormal expression of J-ISPs.

7. Anti-inflammatory activity:

A number of flavonoids are reported to possess anti-inflammatory activity. Hesperidin, a citrus flavonoid possesses significant antiinflammatory and analgesic effects³⁷. Recently, apigenin, luteolin and quercetin have been reported to exhibit antiinflammatory activity. Quercetin, gallic acid ethyl ester and some as yet unidentified flavonoids might account for the antinociceptive action reported for the hydroalcoholic extract of *Phyllanthus caroliniensis*. Treatment with silymarin demonstrated reversal of the carrageenin induced biochemical changes. Detailed biochemical studies to establish mechanism of action of flavonoids have been carried out^{38,39}.

8. Antineoplastic activity:

Quite a number of flavonoids have exhibited antineoplastic activity. Recent reviews have highlighted this activity⁴⁰⁻⁴². Detailed studies have revealed that quercetin exerted a dose dependent inhibition of cell

growth and colony formation. The flavonoids kaempferol, catechin, toxifolin and fisetin also suppressed cell growth^{43,44}. On screening antileukaemic efficacy of 28 naturally occurring and synthetic flavonoids on human promyelocytic leukaemic HL-60 cells, genistein, an isoflavone was found to have strong effect. Genistein is also reported to inhibit in a dose dependent manner the growth of HGC-27 cells derived from human gastric cancer. Of the 14 flavonoids tested against murine and human cancer cell lines, 2',6'-diacetoxy -4,4' -dimethoxydihydro chalcone was the most potent and showed selectivity for the cell line P-388⁴⁵⁻⁵⁰. Trifolirhizin tetraacetate showed greater selectivity for the human cell lines.

9. Effects on blood vessels:

Quercetin and rutin have been used as effective constituents of several pharmaceuticals used for treatment of capillary fragility and phlebosclerosis. The activities of certain flavonoids in inhibiting capillary permeability and Arthus phenomenon were found to be in the following order, hesperitin > rutin > quercetin > naringenin > kaempferol > isoquercitol⁵¹⁻⁵⁴. It has been suggested that flavonoids, which contain free hydroxyl groups at 3, 3' and 4' positions exert beneficial physiological effects on capillaries.

Flavonoids tangeratin, hesperidin, quercetin, and rutin have been found to reduce aggregation of horse erythrocytes. The decrease in blood cell aggregation produced by most of the flavonoids may explain the reported beneficial effects of these compounds on abnormal capillary permeability and fragility, the reduction of disease symptoms and their protection against various traumas and stresses⁵⁵. The flavonoids O-(β - hydroxyethyl) rutoside, (+)- catechol, trihydroxyethylrutoside increased the negative charge density of the blood vessel wall *in vitro* and were markedly antithrombogenic⁵⁶. Quercetin also has been reported to inhibit aggregation of human platelets by several authors. Other antiaggregatory flavonoids reported were 3-methyl quercetin, toxerutin, fisetin, dihydroquercetin and flavone. Nobeletin and sinensetin decreased erythrocyte aggregation and sedimentation *in vitro* and might be useful in dietary control of high blood viscosity syndrome⁵¹⁻⁵⁸. Orally administered flavonoids weakly inhibit the vascular permeability and prevent pulmonary haemor-

rhage. Acacetin at 25-100 mg/kg oral dose to mice reduced capillary fragility and at 50-100 mg/kg it reduced vascular permeability^{57,58}. Patuletin reduced the capillary permeability and was also reported to have antispasmodic and hypotensive effects.

10. Antimicrobial activity:

Flavonoids and esters of phenolic acids were investigated for their antibacterial, antifungal and antiviral activities. All samples were active against the fungal and gram-positive bacterial test strains and most showed antiviral activity⁵⁹.

- i) *Antibacterial Activity*: Antibacterial activity has been displayed by a number of flavonoids. Twenty-five out of one hundred and eighty two flavonoid studies were found to be active against many bacteria. Most of the flavonones having no sugar moiety showed antimicrobial activities where as none of the flavonols and flavonolignans tested showed inhibitory activity on the microorganisms⁵⁹.
- ii) *Antifungal Activity*: Number of flavonoids isolated from peel of tangerine orange, when tested for fungistatic activity towards *Deuterophoma tracheiphila* showed promising activity. Chlorflavonin was the first chlorine-containing flavonoid type antifungal antibiotic produced by strains of *Aspergillus candidus*⁶⁰.
- iii) *Antiviral Activity*: Flavonoids also displayed antiviral, including anti-HIV activity. It has been found that flavonols are more active than flavones against herpes simplex virus type 1 and the order of importance was galangin > kaempferol > quercetin⁶¹. Recently, a natural plant flavonoid polymer of molecular weight 2100 Daltons was found to have antiviral activity against two strains of type-1 herpes type simplex virus, including a thymidine-kinase deficient strain and type -2 herpes simplex virus⁶². Out of twenty-eight flavonoids tested, flavan-3-ol was more effective than flavones and flavonones in selective inhibition of HIV-1, HIV-2 and similar immunodeficiency virus infections⁶³. Details of the flavonoids and their antimicrobial activity were given in Table 2.

Table 2. Antibacterial, antifungal and antiviral activity of various flavonoids.

| Organism | Flavonoids | References |
|-----------------------------------|--|------------|
| Antibacterial activity: | | |
| <i>Staphylococcus aureus</i> | Quercetin, Baicalin, Quercetogetin, Hesperetin, Fisetin, iso-liquiritigenin ⁸³ , Naringin+rutin, Naringin+ Hesperetin | 64 |
| <i>Staphylococcus albus</i> | Fisetin | 65 |
| <i>Streptococcus pyogenes</i> | Apigenin | 66 |
| <i>Streptococcus viridans</i> | Apigenin | 67 |
| <i>Streptococcus jaccalis</i> | Chrysin | 68 |
| <i>Streptococcus baris</i> | Chrysin | 69 |
| <i>Streptococcus pneumoniae</i> | Chrysin | 70 |
| <i>Shigella boydii</i> | Hesperetin, Naringin+Rutin, Naringenin+Hesperetin | 71 |
| <i>Pseudomonas aeruginosa</i> | Rutin, Naringin, Baicalin, Hydroxyethylrutosine | 72 |
| <i>Escherichia coli</i> | Quercetin | 73 |
| <i>Bacillus subtilis</i> | Quercetin | 73 |
| <i>Bacillus anthracis</i> | Rutin | 74 |
| <i>Proteus vulgaris</i> | Datisetin | 76 |
| <i>Clostridium perfringens</i> | Hydroxyethylrutoside | 77 |
| Antiviral activity: | | |
| Rabies virus | Quercetin, Quercetrin, Rutin | 84 |
| Herpes Virus | Quercetin | 85 |
| Para influenza virus | Quercetin, Rutin | 86 |
| Herpes simplex virus type | Galangin, Quercetin, Kempferol | 87 |
| | Apigenin, Chrysin | 88 |
| Potato virus | Morin, Rutin+Quercetin | 89 |
| Influenza virus | Rutin+Quercetin | 89 |
| Herpes simplex virus type 2 | Quercetin | 90 |
| Respiratory syncytial virus | Quercetin, Naringin | 90 |
| Immuno-deficiency virus infection | Apigenin | 91 |
| Auzesky virus | Quercetin, Quercetrin, Morin, Apigenin, Luteolin | 92 |
| Polio virus | Quercetin | 93 |
| Mengo virus | Quercetin | 93 |
| Pseudorabies virus | Quercetin | 93 |
| Antifungal activity: | | |
| <i>Candida albicans</i> | Chloroflavinin | 78 |
| <i>Candida tropicalis</i> | Quercetin | 79 |
| <i>Fusarium solani</i> | Chrysoeriol | 80 |
| <i>Botrytis cinerea</i> | Chrysoeriol | 80 |
| <i>Verticillium dahliae</i> | Chrysoeriol | 80 |
| <i>Azotobacter vinelandii</i> | Quercetin, Rutin, Epicathenin | 81 |
| <i>Alternacia tennisima</i> | Apigenin, Echinacin | 82 |
| <i>Cladosporium herbarum</i> | Phaseolinisoflavan | 83 |

II. Biochemical effects of flavonoids:

(i) On enzymes:

Flavonoids are known to inhibit a number of enzymes such as aldose reductase¹⁰⁷, xanthine oxidase¹⁰⁸, phosphodiesterase¹⁰⁹, Ca²⁺ ATPase¹¹⁰, lipo-oxygenase¹¹¹ and cyclooxygenase¹¹². Flavonols like quercetin, myricetin and kaempferol inhibit the activity of the adenosine deaminase of endothelial cells, while flavones are inactive⁹⁴. Quercetin, morin, myricetin and kaempferol are effective in antagonizing bradykinin responses⁹⁵. Effects of luteolin and quercetin on inhibition of tyrosine kinase, on cell growth and metastasis⁹⁶. They have inhibitory properties on the 5'-nucleotidase (5'- ribonucleotide phosphohydrolyase) activity⁹⁷. Flavonoids inhibit intracellular Ca²⁺ elevation by reducing phospholipase-C activity⁹⁸ and they possess potent inhibitory effects on several enzyme systems such as protein kinase-C, protein tyrosine kinase, phospholipase A2 and others⁹⁹. Flavonoids have high potencies and selectivities for inhibition of CYPIA isoenzymes¹⁰⁰. Silymarin acts a strong antioxidant by virtue of its ability to act as an acceptor of O₂ or CCl₃ radicals. By trapping O₂ related free radicals silymarin hinders their interaction with polyunsaturated fatty acid and abolishes the enhancement of lipid peroxidation. Some flavonoids are predominant inhibitors of either cyclo-oxygenase or lipoxygenase, others are equally effective against both enzymes^{101,102}.

Numerous reports of a high standard have appeared on the inhibition by flavonoids of a perplexing number and variety of enzymes, e.g. hydrolases (such as α -glucuronidase), hyaluronidase, alkaline phosphatase, arylsulphatase, H⁺-ATPases of lysosomal and granular membranes, Na⁺/K⁺-ATPase of the plasma membrane, α -galactosidase, c-AMP phosphodiesterase, lipases, lyases (such as DOPA- decarboxylase), transferases (like catechol-O-methyltransferase), hydroxylases (like aryl hydroxylase), oxidoreductases (like aldose reductase) and kirases (e.g. hexokinase)¹⁰³⁻¹⁰⁶. Apigenin inhibits phosphodiesterase (PDE) and the effect was greater on cAMP-PDE than cGMP-PDE levels by 40 percent and cGMP level remained unchanged. Thus the cardiotoxic action is due to the inhibition of cardiac cAMP-PDE¹¹³⁻¹¹⁴. When one examines these enzymes, which are all influenced by a group of compounds of a rather homogeneous structure, one notices that they seem to

have little in common. Therefore, they apparently interact with different parts of the flavonoid molecule, parts of flavonoid interact with enzymes were given in Table 3.

(ii) On hormones:

Flavonoids have also been shown to have regulatory activity of hormones, by binding to 17 beta-hydroxy steroid dehydrogenases, which regulates estrogen and androgen levels in humans and to 3 beta-hydroxy steroid dehydrogenase, which regulates progesterin and androgen levels in humans¹¹⁵. Quercetin, myricetin, rutin, kaempferol affect the transport, metabolism and action of thyroid hormones. Quercetin myricetin, rutin, kaempferol, galangin, spirenoside and robinin are potent non-toxic ITH deiodinase inhibitors in microsomal membranes, and intact rat hepatocytes. Myricetin, rutin, kaempferol are specific high affinity competitors for L- T4-binding to human TBPA, weaker antagonists in the T3-5'-deiodinase reaction, and very poor inhibitors of T3 binding to the nuclear T3 receptor. Further investigation needs the role of ITH deiodination for tissue specific expression of thyroid hormone action as well advance the knowledge of specific interaction of flavonoids with antithyroidal agent with extra-thyroidal mechanism of action in the process of T₄ bioactivation to the thyromimetically active T₃¹¹⁶.

(iii) Therapeutic potential of flavonoids:

The use of flavonoids in the treatment of diseases is to a large extent is much older than the science of chemistry. In view of the need for safe and effective treatment a study of the role of silymarin in the management of non-B acute viral hepatitis was investigated, which showed significantly earlier recovery from hepatomegaly and enlarged spleen in patients receiving silymarin. Both meciadiol and sofalcone have been studied for antiulcer effectiveness and found to be effective in clinical trials²². Sofalcone has been used clinically in Japan for treatment of gastroduodenal ulcers¹²²⁻¹²⁵. Treatment with hydroxy ethyl rutosides significantly improved the sensation of limb swelling, 'bursting' pain, heaviness, tension and mobility. They have been administered to a small number of patients with Raynaud's syndrome and produced reductions in the number of episodes, relief of pain and healing of ulcers. Improvements in fluorescein angiography-documented skin blood flow, heating

Table 3. Part of flavonoid molecule and its binding with enzymes.

| Enzyme | Part of flavonoid | Reference |
|------------------------------------|--|---------------|
| Adenosine deaminase | Benzopyrone ring | 94 |
| Tyrosine kinase | Phenyl ring | 96 |
| 5'-Ribonucleotide phosphohydrolase | Carbohydrate | 97 |
| Phospholipase-C | Phenyl ring | 98 |
| Protein kinase-C | Phenyl ring | 98 |
| Protein tyrosine kinase | Benzopyrone ring | 99 |
| Phospholipase-A ₂ | Phenyl ring | 99 |
| Cyclooxygenase | Benzopyrone ring | 99 |
| Lipoxygenase | Benzopyrone ring | 101,102 |
| β-galactoside | Carbohydrate | 103,104 |
| β-galactoside | Carbohydrate | 105 |
| β-galacturonidase | Carbohydrate | 103 |
| Hyaluronidase | Carbohydrate | 106 |
| Alkaline phosphatase | Phenyl ring | 103 |
| Aryl sulphatase | Phenyl ring or Benzopyrone ring | 107 |
| DOPA Decarboxylase | Phenyl ring | 110 |
| Lipase | Phenol (Mg ²⁺ Chelator) | 112 |
| ATPase | Benzopyrone ring | 112 |
| c-AMPPhosphodiesterase | Benzopyrone ring | 113 |
| Catechol-O-Methyl transferase | Phenyl ring | 96 |
| Aryl hydroxylase | Benzopyrone ring | 96 |
| Aldose reductase | Methylation of Hydroxy group at C ₆ /C ₈ | 123 |
| Proline hydrolases | Benzopyrone ring | 96,98 |
| Dehydrogenases | Phenyl ring | 99, 111 |
| Xanthine Oxidase | Free hydroxyl group at C ₅ & C ₇ | 145, 146 |
| Phosphodiesterase | Free hydroxyl group at C ₅ & C ₇ | 112 |
| Ca ²⁺ ATPase | Free hydroxyl group at C ₅ & C ₇ | 113, 103, 106 |
| Lipoxygenase | Free hydroxyl group at C ₅ & C ₇ | 114 |

Table 4. Diseases treated with flavonoids.

| Flavonoids | Target | Disease | Reference |
|--|--|--|------------|
| Hydroxyethylrutosides, Quercetin, silymarin. | PG synthesis | Pain and Inflammation, Night cramps, tiredness/heavy legs, oedema/swollen legs, Ankle/leg circumference. | 37, 38, 39 |
| Quercetin | Aldose reductase. | Diabetes mellitus | 107 |
| Rutin/citrin. | Capillary wall (pG) | Allergy | 112 |
| Disodium cromoglycate | H ⁺ ATPase | Allergy | 103-106 |
| Quercetin | Mast cell | Allergy | 112 |
| Quercetin | Capillary wall (PG) | Parodontosis | 38 |
| Quercetin | Na ⁺ /K ⁺ ATPase | Cancer | 40-42 |
| Quercetin | H ⁺ ATPase of lysosomal membrane. | Virus infection, Common cold | 103-106 |
| Quercetin | Arylhydroxylase, Epoxide hydroxylase | Chemical oncogenesis | |
| Sofalcone, Quercetin | PG synthesis | Oral surgery, Stomach, Head ache, Duodenal ulcers. | 21,37,40 |
| Rutin, Quercetin | | | |
| Kaempferol | PAF | Antiulcer | 41 |
| (+)-Cyandanol-3 | | | |
| Mecidanol, Catechins | Gastic H ⁺ /K ⁺ ATPase | Antiulcer | 42 |

and resting pain have been reported in patients with severe arterial insufficiency of the lower legs receiving oral anticoagulants together with short term intravenous hydroxyethyl-rutosides therapy. Considering the number of flavonoids existing, the probability that the choice was less than optimal was high. Some of the diseases in which therapeutic attempts have been made with flavonoids are listed in Table 4.

REFERENCES

1. Kuhnau J. The flavonoids: A class of semi-essential food components: their role in human nutrition. *World Res Nut Diet* 1976;**24**:117-91.
2. Cesarone M R, Laurora G, Ricci A, Belcaco G, Pomante P. Acute effects of Hydroxiethylrutosides on capillary filtration in normal volunteers, patients with various hypotension and in patients with diabetic micro angiopathy. *J Vas Disease* 1992;**21**:76-80.
3. Bors W, Heller W, Michel C, Saran M, Flavonoids as anti-oxidants: Determination of radical scavenging efficiencies. *Methods Enzymol.*, 1990;**186**:343-55.
4. Colerige Smith PO, Thomas P, Scurr JH, Dormandy JA. Causes of various ulceration, a new hypothesis. *Br Med J* 1980;**296**:1726-7.
5. Clack W, Mackay E. Effect of flavonoid substances on histamine toxicity, anaphylactic shock and histamine enhanced capacity to dye. *J Allergy* 1950;**21**:133-147.
6. Hertog MGL, Hollman PCH, Katan MB, Klomhout D. Intake of potentially anticarcinogenic flavonoids and their determinants in adults in the Netherlands. *Nutr Cancer* 1993;**20**:21-9.
7. Mori A, Nishinoc, Enoki N, Tavata S. Cytotoxicity of plant flavonoids against Hela cells. *Phytochemistry* 1988;**27**: 1017-20.
8. Harsteen B, Flavonoids. A class of natural products of high pharmacological potency. *Biochem Pharmacol* 1983;**32**: 1141-8.
9. Middleton E. The flavonoids. *Trends Pharmacol Sci* 1984;**5**: 335-8.
10. Griebel G, Perrault G, Tan S, Schoemaker H, Sanger DJ. Pharmacological studies on synthetic flavonoids: comparison with diazepam. *Neuropharmacology* 1999;**38**:965-77.
11. Lackeman GM, Claeys M, Rwangabo PC, Herman AG, Vlietinck A. Chronotropic effect of quercetin on guinea pig right atrium. *J Planta Med* 1986;**52**:433-9.
12. Huesken BCP, Dejong J, Beekman B, Onderwater RCA. Flavonoids as cardio protective agents. *Cancer Chemother Pharmacol* 1995;**37**:55-62.
13. Sanchez De RVR, Somoza B, Ortega T, Villar A. Flavonoids action on heart. *Planta Med* 1996;**62**:554-62.
14. Itoigawa M, Takeya K, Ito C, Furu Kawa H. Structure activity relationship of cardiotoxic flavonoids in guinea pig papillary muscle. *J Ethnopharmacol* 1999;**65**:267-72.
15. De-Whalley C, Rankin SM, Houct JRS, Jessup W, Leake DS. Flavonoids inhibit the oxidative modification of low density lipoproteins by macrophages. *Biochem Pharmacol* 1990;**39**:1743-50.
16. Francel EN, Kanner J, German JB, Packs E, Kinsella JE. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. *Lancet* 1993;**341**:454-7.
17. Igarashi K, Ohmura M. Effect of Isoharnneti, Rhamnetin and Quercetin on the concentrations of cholesterol and lipoperoxide in the serum and liver and on the blood and liver antioxidative enzyme activities in rats. *Biosci Biotech Biochem* 1995;**59**:595-601.
18. Fuhrman B, Lavy A, Aviram M. Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoproteins to lipid peroxidation. *Am Soc Clin Nutr* 1995;**61**:549-54.
19. Mc Anlis GT, Mc Enany J, Pearce J, Young IY. The effect of various dietary flavonoids on the susceptibility of low-density lipoproteins to oxidation *in vitro* using both metallic and nonmetallic oxidising agents. *Biochem Soc Trans* 1997;**25**:142-8.
20. Raj KJ, Shalinikapoor. Flavonoids- A review of biological activities. *Indian Drugs* 1999;**36**:668-78.
21. Alarcon DLLC, Martin MJ, Lacasa C, Motilva V. Antiulcerogenic activity of flavonoids and gastric protection. *J Ethnopharmacol* 1994;**42**:161-70.
22. Parmar NS, Shikha Parmar. Anti-ulcer potential of flavonoids. *Indian J Physiology and Pharmacology* 1998;**42**:343-51.
23. IZZOAA, Carlo GD, Mascolo N, Capasso F, Autore G. Effects of quercetin on gastrointestinal tract: further studies. *Phyto Ther Res* 1994;**8**:179-85.
24. Carlo GD, Autore G, IZZOAA, Moiolino P, MascoloN, Viola P, Diurno MV, Capawa F. Inhibition of intestinal motility and secretion by flavonoids in mice and rats; structure-activity relationships. *J Pham Pharmacol* 1993;**45**:1045-59.
25. Lorenz W, Kusche J, Barth H, Mathias CH. Action of several flavonoids on enzyme of histidine metabolism *in vitro*. In Histamine pp. 265-269 (Ed. Cz. Maslinski) Dowden, Hutchinson and Ross. Stroudsburg. Pennsylvania, 1973.

26. Ruiyc. Advances in pharmacological studies of silymarin. *Mem Inst Oswaldo Cruz* 1991;**86**:79-85.
27. Scevola D, Bacbacini G, Grosso A, Bona S, Perissoud D. Flavonoids and hepatic cyclic monophosphates in liver injury. *Boll Ins Sieroter Milan* 1984;**63**:77-82.
28. Wegener T, Fintelmann V. Flavonoids and Bioactivity. *Wein Med Wochem Schr* 1999;**149**:241-7.
29. Ares JJ, Outt PE. Gastroprotective agents for the prevention of NSAID- induced gastropathy. *Curr Pharm Des* 1998;**4**:7-36.
30. Santos AC, Vyemura SA, Lopes JL, Bazon JN, Mingatto FE, Curtic. Effect of naturally occurring flavonoids on lipid peroxidation and membrane permeability transition in mitochondria. *Free Radic Biol Med* 1998;**24**:1455-61.
31. Hillwell B. Free radicals, antioxidants and human disease: curiosity, cause or constipation? *Lancet* 1994;**344**:721-4.
32. Fraga CG, Mactino US, Ferraro GE, Coussio JF, Boveris A. Flavonoids as antioxidants evaluated by *in vitro* and *in situ* liver chemiluminescence. *Biochem Med Metabol Biol* 1987;**36**:717-20.
33. Ratty AK. Effects of flavonoids on nonenzymatic lipid peroxidation: structure-activity relationship. *Biochem Med Metabol Biol* 1988;**39**:67-79.
34. Robak J, Glyglewski RJ. Flavonoids are scavengers of superoxide anions. *Biochem Pharmacol* 1988;**37**:837-41.
35. Husain SR, Cillard J, Cillard P. Hydroxy radical scavenging activity of flavonoids. *Phytochemistry* 1987;**26**:2489-92.
36. Laughton MJ, Halliwell B, Evans PJ, Hoult JRS. Antioxidant and pro-oxidant actions of the plant phenolics quercetin, morin, glossypol and myricetin effects on lipid peroxidation, hydroxy radical generation and bleomycin dependent damage to DNA. *Biochem Pharmacol* 1989;**38**:2859-65.
37. Shahidi F, Yang Z, Saleemi ZO. Natural flavonoids as stabilizers. *J Food Lipids* 1998;**1**:69-75.
38. Morino M, Tsuzuki T, Ishikawa Y, Shirakami T, Yoshimura M, Kiyosuke Y, Matsunaga K, Yoshikumi C, Saijo N. Specific regulation of HSPs in human tumour cell lines by flavonoids. *In vivo* 1997;**11**:265-70.
39. Alcaraz MJ, Ferrandiz ML. Modification of arachidonic metabolism by flavonoids. *J Ethnopharmacol* 1987;**21**:209-29.
40. Kontruck SJ, Radecki T, Brozowski T, Drozdowicz D, Piastucki I, Muramatsu M, Tanaka M, Aihara H. Anti-ulcer and gastroprotective effects of solon, a synthetic flavonoid derivative of sophorandin. Role of endogenous prostaglandins. *Bur J Pharmac* 1986;**125**:185-92.
41. Izzo AA, Dicarlo G, Mascolo N, Capasso F, Autore G. Anti-ulcer effects of flavonoids. Role of Endogenous PAF. *Phytotherapy Res* 1991;**8**:179-81.
42. Murakami S, Muramatsu M, Otomo S. Gastric H⁺/K⁺ ATPase inhibition by catechins. *J Pharm Pharmacol* 1992;**44**:926-8.
43. Kim HK, Namgoong SY, Kim HP. Biological actions of flavonoids-I. *Arch Pharmacol Res* 1993;**16**:18-27.
44. Gill B, Sanz MJ, Terencio MC, Ferrandiz ML, Bustos G, Paya M. The flavonoids. *Life Sci* 1994;**54**:333-9.
45. Hirano T, Gotoh M, Oak K. Natural flavonoids and lignans are plant cytostatic agents against Human Leukemic HL-60 cells. *Life Sci* 1994;**55**:1061-9.
46. Wei H, Tye L, Bresnick E, Birt DF. Inhibitory effect of Apigenin, a plant flavonoid on epidermal ornithine decarboxylase skin tumour promotion in mice. *Cancer Res* 1990;**50**:499-502.
47. Block G, Patterson B, Sufai A. Fruits, vegetables and cancer prevention: A review of the epidemiological evidence. *Nutr Cancer* 1992;**18**:1-29.
48. Hirose M, Hoshiya T, Akagi T, Takalashi S, Hara Y. Effect of green tea catechin in a rat multi-organ carcinogenesis model. *Carcinogenesis* 1993;**14**:1549-53.
49. Hertog MGL, Hollman PCH, Katan MB, Kromhout D. Intake of potentially anticarcinogenic flavonoids and their determinants in adults in the Netherlands. *Nutr Cancer* 1993;**20**:21-29.
50. Hirano T, Oka K, Akiba M. Antiproliferative effects of synthetic and naturally occurring flavonoids on turner cells of the human breast carcinoma cell line, 2R-75-1. *Res Commun Chem Pahol Pharmacol* 1989;**64**:69-78.
51. Felicia VS, Najla G, Ann PC, Madeleine M, Keneeth KC. Inhibition of Human Breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoides and citrus juices. *Nutr Cancer* 1996;**26**:167-81.
52. Catherine C, Malc S, Esther HL, Vadimir A, Krutorslaikh, *et al*. Lack of tumour-Promoting effects of flavonoids: studies on rat liver preneoplastic foci and on *In vivo* and *In vitro* gap junctional inter cellular communication. *Nutr Cancer* 1996;**26**:251-63.
53. Paul P, Ritva J, Ritva S, Mackku H, Lyly T, Eero P, Arpo A. Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. *Am J Epidemiolo* 1997;**146**:223-30.

54. Fritz B, Tobias S, Albrecht K, Chaelotte B, Kent C, *et al.* Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase-I. *J Biol Chem* 1996;**271**:2262-70.
55. Versantvoort CH, Schuurhuis GJ, Pinedo HM, Bekman CA, Kuiper CM, *et al.* Genistein modulates the decreased drug accumulation in non-p-glycoprotein mediated multidrug resistant tumor cells. *Br J Cancer* 1993;**68**:939-46.
56. Griffith LA, Ballow A. The fate of orally and parenterally administered flavonoids in the mammal, the significance of biliary excretion. *Angiologica* 1972;**9**:162-74.
57. Mc Ewan AJ, Mc Arde CS. Effect of Hydroxyethylrutosides on blood oxygen levels and venous insufficiency symptoms in varicose veins. *Br Med J* 1971;**2**:138-41.
58. Wenner A, Leu HJ, Spycher M, Brunner U. Ultra structural changes of capillaries in chronic venous insufficiency. *Exp Cell Biol* 1980;**48**:1-14.
59. Wild C, Fasel J. Effect of a flavonoid on the capillary resistance of the rectal mucosa in hepatic cirrhosis. *Am J Proct* 1969;**20**:60-2.
60. Tencate JW, Van Haeringen NJ, Gerritsen J, Glasius E. Biological activity of a semisynthetic flavonoid, O-(β -Hydroxyethyl) Rutosine: Light- scattering and metabolic studies of human red cells and platelets. *Clin Chem* 1973;**19**:31-5.
61. Thomas PRS, Nash GB, Dormandy JA. White cell accumulation in dependant legs of patients with venous hypertension: A possible mechanism for trophic changes in the skin. *Br Med J* 1988;**296**:1673-95.
62. Loewenstein WR. Junctional Intercellular communication and the control of growth. *Biochem Biophys Acta* 1979;**560**:1-65.
63. Gerdin B, Srenso E. Inhibitory effect of the flavonoids on increased microvascular permeability induced by various agents in rat skin. *Int J Micro Cir Clin Exp* 1983;**2**:39-46.
64. Kujumgier A, Tsvetkova J, Serkedjieva Y, Bankova V, Christov R, Popov S. Antibacterial, antifungal and antiviral activity of propolis of different geographic origin. *J Ethno Pharmacol* 1999;**64**:235-40.
65. Weidenboemer M, Jha HC. Inhibition of fungal infections of flavonoids. *Pestic Sci* 1993;**38**:347-53.
66. Amoros M, Simoes CMO, Girre L, Sauvanger F, Cormier M. Inhibition of HIV infection by Baicalin- A flavonoid compound purified from chinese herbal medicine. *J Nat Prod* 1992;**55**:1732-9.
67. Bamard DL, Smer DF, Hoffman JH, Meyerson LR, Sidwell RW. Pharmacological properties offlavonoids. *Chemotherapy* 1993;**39**:203-9.
68. Mahmood N, Pizza C, Aquino R, De Tammasi N, Piacente S, Colman S, Bruke A, Hay AJ. Inhibition of HIV infection by flavonoids. *Antiviral Res* 1993;**22**:189-97.
69. Naghski J, Copley MJ, Couch JF. Antifungal activity of plant polyphenols. *Science* 1947;**105**:125-31.
70. Tereschuk ML, Riera MVQ, Casteo GR, Afdala LR. Antimicrobial activity of flavonoids from leaves of *Tagetes minuta*. *J Ethnopharmacol* 1997;**56**:227-36.
71. Gabor M, Eperjessy E. Antimicrobial activity of flavonoids from leaves of chinese herb. *Nature* 1966;**212**:1273-9.
72. Ng TB, Ling JML, Wang ZT, Cai JN, Xu GJ. Examination of coumarins, flavonoids and poly saccharopeptides for anti fungal activity. *Gen Pharmacol* 1996;**27**:1237-42.
73. Ran SS, Lee CK, Kim YS. Characteristics and occurrence of plant polyphenols. *Yak Hak Hoechi* 1992;**36**:407-14.
74. Bashir AK, Abdulla AA, Wasti IA, Wassan ES, Amiri MH, Crabb TA. New bioactive flavonoids incube resin insecticide. *Int J Pharmcogn* 1994;**34**:366-72.
75. Kais N, Rahman MM, Rashid MA, Koshinoh, Nagasawa K, Nakata T. Effect of flavonoid compounds on the immune system. *Fitoterapia* 1996;**67**:554-61.
76. Ishii E, Odate J, Ogma T, Myata T. Flavonoids: New aspects of a class of natural therapeutic drugs. *Chem Abste* 1995;**122**:1969544.
77. Ratsimamanga VS, Rasoanaivo P, Rafemanantsoa C, Ratsimamanga AR, frappier F. Effect of Quercetin on *Staphylococcus aureus* *in vitro*. *Fitoterapia* 1994;**65**:551-8.
78. Pham TK, Vinh PT, Nong HD, Nguyen DK. Flavonoids as antimicrobial agents. *Tap chi Duoc Hoc* 1993;**6**:14-21.
79. Sato M, Fujiwara S, Tsuchiya H, Fujii T, Linuma M, Tosa H, Ohkawa Y. Role of flavonoids in microbial diseases. *J Ethnopharmacol* 1996;**54**:171-8.
80. Sanabria GA, Ospina SA, Ceron JA, Raman MJ. Quercetin and related bioflavonoids: A review. *Rev Colomb Cienc Quim Farm* 1991;**19**:44-51.
81. Nishino C, Enoki N, Tawata S, Mori A, Kobayashi K, Fukushima M. Tea flavonoids and microbial disease: A review. *Agric Biol Chem* 1987;**51**:139-45.
82. Pathak D, Pathak K, Singla AK. Flavonoids as medicinal agents- Recent evidences. *Fitoterapia* 1991;**XII(5)**:371-89.
83. Marchelli R, Vining LC. Recent advances in the discovery

- and development of flavonoids and their antiviral activity. *JCS Chem Comm* 1973;555.
84. Ghazal SA, Abuzarqua M, Mahansneh AM. Effect of plant flavonoids on immune and inflammatory cell function. *Phytother Res* 1992;6:265-71,
 85. Kell KP, Manadi AM, Adiyasora ZF, Kunaera RM, IZV. Akad. Naun. Kaz. SSR. Bioflavonoids and health effects in man. *Chem Abst* 1987;107:36667.
 86. Deca RT, Gouzalez IJ, Mactinez TMV, Moreno J, Romo SCA. Soil Biol. *In vitro* antifungal activity of some flavonoids and their metabolites. *Biochem* 1987;19: 223-31.
 87. Singh UP, Pandey VB, Singh KN, Singh RON. Structural and biogenic relationships of isoflavonoids. *Can J Bot* 1988;166:1901-10.
 88. Tahara S, Hashidoka Y, Mizutani J. Flavonoids as medicines. *Agri Biol Chem* 1987;51:1039-45.
 89. Tripathi VD, Rastogi RP. *In vitro* anti-HIV activity of flavonoids isolated from *Garcinia multifolia*. *J Sci Indian Res* 1981;40:116-21.
 90. Bakay M, Mucci I, beladi I, Gabor MM. Antiviral flavonoids from *Alkena orientalis*. *Acta Microbiol* 1968;15:223-32.
 91. Tsuchiva Y, Shimizu, Hiyama Y, Itoh K, Hashimoto Y, Nakarama M, Horie T, Morita N. Inhibitory effect of flavonoids on fungal diseases. *Chem Pharm Bull* 1985; 33:3881-90.
 93. Hayashi K, Hayashi T, Arisawa M, Morita N. *In vitro* inhibition of viral disease by flavonoids. *Antiviral Chem Chemother* 1993;4:49-58.
 94. Nagai T, Miyaichi Y, Tomimori T, Suzuki Y, Yamaha H. Antiviral activity of two flavonoids from *Tanacetum microphyllum*. *Antiviral Res* 1992;19:207-16.
 95. Bamard DL, Smee DF, Huffman JH, Meyerson CR, Sidwell RW. Review of Quercetin and related bioflavonoids. *Chemotherapy* 1993;39:203-11.
 96. Hur CQ, Chen K, Shi Q, Kilkuskie RE, Cheng YC, Lee KH. Apoptosis of HIV infected cell following treatment with Shosikorso. *J Nat Prod* 1994;57:42-50.
 97. Beladi I, Musci I, Pusztai R, Bakay M, Rosztoczy I, Gabor M. Bioactivity of flavonoids. *Stud Org Chem* 1987;1:443.
 98. Musci I, Pragathi M. The nutritional significance of flavonoids, some physiological consideration. *Experientia* 1985; 41:930.
 99. Melzig MF. Inhibition of adenosine deaminase activity of aortic endothelial cells by selected flavonoids. *Planta Med* 1996;62:1-20.
 100. Calixto JB, Yunes RA. Natural bradykinin Antagonists. *Mem Inst Oswaldo Cruz* 1991;86:195-202.
 101. Huang Y, Hwang J, Lee P, Ke F, Huang J, Huang C, Kanda Swamic, JrBM, Lee M. Effects of Luteolin and Quercetin inhibitors of tyrosine kinasa on cell growth and metastasis- associated properties in A43Al cells over expressing epidermal growth factor receptors. *Br J Pharmacol* 1999; 128:999-1010.
 102. Kavutru M, Melzig MF. *In vitro* effects of selected flavonoids on the 5'- nucleotidase activity. *Pharmazine* 1999;54:457-9.
 103. Kyo R, Nakalata N, Sakakifara I, Kubo M, Ohizumi Y. Baicalin and Baicalein constituents of an important medicinal plant, inhibit intracellular Ca⁺² elevation by reducing phospholipase-C activity in C6 rat glioma cells. *J Pharm Pharmacol* 1998;50:1179-82.
 104. Middleton E Jr. Effect of plant flavonoids on immune and inflammatory cell function. *Adv Exp Med Biol* 1998;439:175-82.
 105. Zhai S, Dai R, Friedman FK, Vestal RE. Comparative inhibition of human cytochrome P₄₅₀ 1A1 and 1A2 by flavonoids. *Drug Metabol Dispos* 1998;26:989-92.
 106. Zhai S, Dai R, Wei X, Friedman FK, Vestal RE. Inhibition of methoxyresorufin demethylase activity by flavonoids in human liver microsomes. *Life Sci* 1998;63:119-23.
 107. Jager W, Zemsch B, Wolschann P, Pittenauer E, Senderavicz AM, et al. Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases in rat liver. *Life Sci* 1998;62:1861-73.
 108. Koch HP, Jager W, Groh U, Plank G. *In vitro* inhibition of adenosine deaminase by flavonoids and related compounds. New insight into the mechanism of action of plant phenolics. *Methods Find Exp Clin Pharmacol* 1992;14:413-17.
 109. Alcaraz MJ, Ferrandiz ML. Modification of arachidonic metabolism by flavonoids. *J Ethnopharmacol* 1987;21:209-29.
 110. Scerola D, Barbarini G, Grosso A, Bona S, Perissoud D. Flavonoids and hepatic cyclic monophosphates in liver injury. *Boll 1st seiroter milan* 1984;63:77-82.
 111. Baumann J, Von Brucchau Sen F, Wurm G. Flavonoids and related compounds as inhibition of arachidonic acid peroxidation. *Prostaglandins* 1980;20:627-39.
 112. Varma SD, Kinoshita JH. Inhibitory effects of plant polyphenols on rat liver glutathione-S-transferase. *Biochem Pharmacol* 1976;25:2505-10.

113. Okuda J, Miwa I, Inagaki, Hari T, Nakayama M. *In vivo* and *In vitro* glucuronidation of the flavonoid diosnetin in rats. *Chem Pharm Bull* 1984;**32**:767-72.
114. Beiler JM, Mactin GJ. Flavonoids as protein tyrosine kinase inhibitors. *J Biol Chem* 1951;**192**:831-40.
115. Noro T, Oda Y, Miyasa, Ueno A, Fukushima S. Inhibition of adenosine deaminase activity of aortic endothelial cells by selected flavonoids. *Chem Pharm Bull* 1983;**31**:3984-91.
116. Petkov E, Nickdor N, Uzunov P. Inhibitory effects of flavonoids on xanthine oxidase. *Planta Med* 1981;**43**:183-87.
117. Fervtrael CMS, Caomperts BD. Flavonoids and the inhibition of Pk-C and P₁₃-kinase. *Nature* 1977;**265**:635-9.
118. Sekiya S, Okuda H. *In vitro* inhibition of phosphodiesterase by flavonoids. *Biochem Biophys Res Commun* 1982;**105**:1090-7.
119. Baumann J, Wurm G, Bruchhausen H. Heterogeneous effects of natural flavonoids on monooxygenase activity in human and rat liver microsomes. *Arch Pharm* 1980;**313**:330-7.
120. Baker ME. Endocrine activity of plant-derived compounds: an evolutionary perspective. *Proc Soc Exp Biol Med* 1995;**208**:131-8.
121. Kohrle J, Spanka M, Irmscher K, Hesch RD. Flavonoid effects on transport, metabolism and action of thyroid hormones. *Prog Clin Biol Res* 1988;**280**:323-40.
122. Nomura K, Iwama T, Honda K, Murata M. Chemical evaluation of SU-88 against gastric ulcer. Long term study. *Japan Pharmacol Ther* 1982;**10**:1.
123. Hirasawa T, Shoji T, Hoshino E, Saito Y, Okamoto R, Anno E, Endo K, Sizuki A. Clinical study of effect of SU-88 on gastric ulcer combination of treatment. *Japan Pharmacol Ther* 1982;**10**:5.
124. Gomi K, Kwayama H, Abe M, Okada S, Tanaka S, Tanaka Y. Clinical evaluation of SU-88 on peptic ulcer. *Japan Pharmacol Ther* 1982;**10**:1.
125. Sankawa U. In proceedings of the seventh Asian symposium on medicinal plants, spices and other natural products, Eds. Cruz LJ, Concepcion GP, Mendigo MAS and Guevara. B.Q. University of Philippines, Manila, 1992, p. 143.

LOW DOSE ASPIRIN MAY HELP TO PREVENT PRE-ECLAMPSIA DURING PREGNANCY

A study in BMJ shows that antiplatelet drugs, largely low dose aspirin, have small to moderate benefits when used for prevention of pre-eclampsia and its complications during pregnancy.

Duley and colleagues reviewed 39 trials, involving over 30,000 women at risk of developing pre-eclampsia. Their findings suggest that antiplatelet drugs are associated a moderate (15%) reduction in the risk of pre-eclampsia, a 14% reduction in the risk of stillbirth or neonatal death, and an 8% reduction in the risk of preterm birth.

As the reductions in risk are moderate, relatively large numbers of women will need to be treated to prevent the death of one baby, explain the authors. However, from a public health perspective, even these moderate benefits may be worthwhile. Data from individual women need to be reviewed to identify which women are most likely to benefit, when treatment should be started, and at what dose, they conclude.

Source: Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review, BMJ 10th February 2001. Full article available at <http://bmj.com/cgi/content/full/322/7282/329>